Munich, Germany

Elisabeth Nahrwold

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 8.3

ph-index = 4

Forward Citations = 61(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):

Title: Elisabeth Nahrwold: Pioneering Innovator in Antibody Constructs

Introduction: Elisabeth Nahrwold, based in Munich, Germany, is a remarkable inventor known for her significant contributions to the field of biotechnology. With a total of 9 patents to her name, she has made strides in developing innovative treatments through her research and inventions in antibody constructs.

Latest Patents: Elisabeth Nahrwold's recent patents focus on bispecific antibody constructs that target specific proteins in cancer treatment. Her inventions include:

1. **Antibody Constructs for MSLN and CD3** - This invention relates to a bispecific antibody construct that features a binding domain for human Mesothelin (MSLN) on a target cell and another binding domain for human CD3 on T cells. It also covers a polynucleotide encoding this antibody construct, associated vectors, and methods of production, along with medical applications and kits containing the constructs.

2. **Antibody Constructs for CLDN18.2 and CD3** - This patent involves an antibody construct that binds to Claudin 18.2 (CLDN18.2) and CD3, further detailing the polynucleotide encoding, vectors, host cells, production processes, medical uses, and kits associated with the antibody construct.

Career Highlights: Elisabeth has garnered invaluable experience working with esteemed organizations. She spent a significant portion of her career at Amgen Research GmbH in Munich and Amgen Inc., where her expertise in biotechnology flourished. Her work has played a crucial role in the development of innovative biopharmaceuticals focused on cancer treatment.

Collaborations: Throughout her career, Elisabeth Nahrwold has collaborated with talented professionals, including her coworkers Tobias Raum and Patrick Hoffmann. These partnerships have been instrumental in advancing her research and the successful development of her patented technologies.

Conclusion: Elisabeth Nahrwold exemplifies the spirit of innovation in the biotechnology sector. Her patents highlight her dedication to advancing therapeutic options through groundbreaking research in antibody constructs. As she continues to contribute to the scientific community, her work paves the way for future developments in medical treatment and technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…